flonotinib

Flonotinib (ZL-2102) is a potent and highly selective Janus kinase 2 (JAK2) inhibitor developed by Chengdu Zeling Biomedical Technology. It is specifically designed to target the JAK2/STAT3 signaling pathway, which is frequently dysregulated in myeloproliferative neoplasms. Unlike first-generation JAK inhibitors that often inhibit both JAK1 and JAK2, flonotinib's high selectivity for JAK2 is intended to reduce off-target toxicities such as anemia and thrombocytopenia associated with JAK1 inhibition. It is currently being evaluated in clinical trials for the treatment of intermediate-2 or high-risk myelofibrosis, including patients who are refractory, relapsed, or intolerant to prior JAK inhibitor therapies like ruxolitinib.

Other names

flonotinib maleate马来酸氟诺替尼